

**Table 3.** T cell response to AFP and AFP-derived peptides by ELISPOT assay before and after TAE with DC infusion

| Patient | HLA     | Additional treatment | Complete ablation | Before treatment |                               |                    |                    |                    |           |                        |           | After treatment |                               |                    |                    |                    |           |                        |           |
|---------|---------|----------------------|-------------------|------------------|-------------------------------|--------------------|--------------------|--------------------|-----------|------------------------|-----------|-----------------|-------------------------------|--------------------|--------------------|--------------------|-----------|------------------------|-----------|
|         |         |                      |                   | AFP (ng/ml)      | Lymph. ( $\mu\text{l}^{-1}$ ) | AFP <sub>357</sub> | AFP <sub>403</sub> | AFP <sub>434</sub> | AFP       | CMVpp65 <sub>328</sub> | TT        | AFP (ng/ml)     | Lymph. ( $\mu\text{l}^{-1}$ ) | AFP <sub>357</sub> | AFP <sub>403</sub> | AFP <sub>434</sub> | AFP       | CMVpp65 <sub>328</sub> | TT        |
| 21      | A24     | No                   | –                 | 332              | 1,100                         | 7                  | 1                  | 4                  | ND        | <b>10</b>              | ND        | 819             | 800                           | 11                 | 0                  | <b>10</b>          | ND        | <b>188</b>             | ND        |
| 22      | A24,A26 | RF                   | N                 | 341              | 700                           | 0                  | <b>26</b>          | 5                  | ND        | <b>68</b>              | ND        | 237             | 500                           | ND                 | <b>59</b>          | ND                 | ND        | <b>81</b>              | ND        |
| 23      | A11,A24 | No                   | –                 | 41               | 600                           | 0                  | 2                  | 5                  | 1         | 2                      | 0         | 43              | 400                           | 0                  | 0                  | 0                  | 0         | 0                      | 3         |
| 24      | A2,A24  | MCT                  | C                 | 1,260            | 800                           | 3                  | 8                  | 7                  | ND        | <b>19</b>              | ND        | 614             | 1,300                         | <b>26</b>          | 4                  | 7                  | ND        | <b>12</b>              | ND        |
| 25      | A24,A33 | RF                   | C                 | 11               | 1,500                         | 0                  | 1                  | 0                  | <b>31</b> | 5                      | <b>15</b> | 19              | 900                           | 1                  | 4                  | <b>15</b>          | <b>26</b> | 3                      | 4         |
| 26      | A24,A33 | RF                   | C                 | <10              | 2,000                         | 0                  | 0                  | 0                  | 0         | 0                      | 0         | <10             | 1,700                         | 0                  | <b>16</b>          | 0                  | 0         | 0                      | 0         |
| 27      | A24,A26 | RF                   | C                 | 16               | 700                           | 0                  | 0                  | 0                  | 1         | 1                      | 0         | 16              | 700                           | 2                  | 1                  | <b>15</b>          | 9         | 0                      | 1         |
| 28      | A11,A31 | RF                   | N                 | 31               | 800                           | ND                 | ND                 | ND                 | 3         | ND                     | 0         | 33              | 700                           | ND                 | ND                 | ND                 | 0         | ND                     | 0         |
| 29      | A11,A33 | No                   | –                 | <10              | 1,100                         | ND                 | ND                 | ND                 | 0         | ND                     | 0         | <10             | 700                           | ND                 | ND                 | ND                 | 0         | ND                     | 1         |
| 30      | A2,A11  | RF                   | C                 | 13               | 1,300                         | ND                 | ND                 | ND                 | 8         | ND                     | 1         | 14              | 1,500                         | ND                 | ND                 | ND                 | <b>12</b> | ND                     | 7         |
| 31      | A24,A33 | RF                   | C                 | 1,014            | 800                           | 0                  | 0                  | 0                  | 0         | 1                      | 0         | 15              | 300                           | 0                  | 0                  | <b>20</b>          | 0         | 0                      | 0         |
| 32      | A11,A24 | RF                   | C                 | <10              | 1,000                         | 3                  | 3                  | <b>11</b>          | <b>48</b> | <b>97</b>              | 0         | 10              | 1,200                         | <b>23</b>          | <b>20</b>          | <b>20</b>          | <b>45</b> | <b>91</b>              | <b>23</b> |
| 33      | A2,A26  | RF                   | C                 | 29               | 1,300                         | ND                 | ND                 | ND                 | 0         | ND                     | 0         | 27              | 1,300                         | ND                 | ND                 | ND                 | 0         | ND                     | 0         |

Abbreviations: Lymph., number of lymphocytes; RF, radiofrequency ablation; PEIT, percutaneous ethanol injection therapy; MCT, microwave coagulation therapy; C, completed; N, not completed; –, not determined; ND, not done. The bold letters show the positive responses in ELISPOT assays.

Table 4. Patient characteristics

|   | Patients treated by TAE (n = 20) | Patients treated by TAE with DC (n = 13) | p-value <sup>1</sup> |
|---|----------------------------------|--|----------------------|
| Age (years) <sup>2</sup>                                      | 66.6 ± 7.8                       | 65.7 ± 10.0                              | NS                   |
| Sex (M/F)   | 14/6                             | 11/2                                     | NS                   |
| HLA (A23 or 24/others)  | 16/4                             | 9/4                                      | NS                   |
| ALT (IU/l)  | 51.0 ± 47.4                      | 86.9 ± 62.8                              | NS                   |
| Total bilirubin (g/dl)  | 1.3 ± 0.9                        | 1.5 ± 0.9                                | NS                   |
| Albumin (g/dl)  | 3.7 ± 0.7                        | 3.2 ± 0.6                                | NS                   |
| AFP level (ng/ml)   | 322.7 ± 793.0                    | 239.8 ± 418.2                            | NS                   |
| Diff. degrees of HCC (well/moderate or poor/ND <sup>3</sup> ) | 2/6/12                           | 4/4/5                                    | NS                   |
| Tumor size (small/large <sup>3</sup> )                        | 4/16                             | 1/12                                     | NS                   |
| Tumor multiplicity (multiple/solitary)                        | 18/2                             | 12/1                                     | NS                   |
| TNM stage (I, II/III, IV)                                     | 19/1                             | 11/2                                     | NS                   |
| Histology of nontumor liver (LC/chronic hepatitis)            | 15/5                             | 10/3                                     | NS                   |
| Liver function (Child A/B or C)                               | 14/6                             | 3/10                                     | 0.02                 |
| Etiology (HCV/HBV/others)                                     | 12/2/6                           | 13/0/0                                   | NS                   |

<sup>1</sup>Abbreviations: NS, no statistical significance; ND, not determined. <sup>2</sup>Data are expressed as the mean ± SD. <sup>3</sup>Small: ≤2 cm, large: >2 cm.




Figure 2. Frequency of the patients who showed enhancement of T-cell responses after treatment. The prevalence of antigen-specific T cells was determined by IFN- $\gamma$  ELISPOT analysis using alpha-fetoprotein (AFP) and AFP-derived peptides (a), CMV pp65-derived peptide (b) or tetanus toxoid protein (c) in 20 and 13 patients with HCC who received TAE and TAE with DC infusion, respectively.

in 4 and 6 patients who did and did not show increasing AFP-specific T-cell responses, respectively.


#### Kinetics of AFP-specific T-cell responses before and after TAE

Next, we examined the kinetics of AFP-specific T cells in 8 patients who showed increasing frequency of IFN- $\gamma$ -producing T cells against AFP or AFP-derived peptides after TAE. The frequency was examined by ELISPOT assay before and 2–4 weeks and 3 months after TAE. Thirteen kinds of AFP-specific T cells showed increasing frequency 2–4 weeks after TAE (Fig. 4); however, the increase was transient and most cell types decreased 3 months after TAE. Three patients showed more than 10 specific spots for AFP or AFP-derived peptides 3 months after TAE (Patients 6, 11 and 30). In analysis of the correlation between the maintenance of AFP-specific T-cell responses and HCC recurrence, 1 patient (Patient

6) had HCC recurrence after 6 months and 1 patient (Patient 30) did not show recurrence. Another patient (Patient 11) did not receive curative ablation and was not analyzed. There was no difference in the kinetics of AFP-specific T cells between patients who received TAE with and without DC infusion.

#### Discussion

In a previous study, we made a preliminary report that immune responses specific for tumor antigens were enhanced after HCC treatments.<sup>7,10</sup> Similarly, as in our previous or other group's results,<sup>8</sup> we observed enhancement of AFP-specific immune responses in 6 of 20 patients with TAE alone in this study. The enhancement of tumor antigen-specific immune responses was also observed in the cases using MRP3- or hTERT-derived peptides.



**Figure 3.** Comparison of direct *ex vivo* analysis (IFN- $\gamma$  ELISPOT assay) before and after treatment of HCC. The assay was performed using PBMCs of patients who received TAE for AFP-derived peptides (a), AFP (b), CMV pp65-derived peptide (c) or tetanus toxoid protein (d). The same assay was performed using PBMCs of patients who received TAE with DC infusion for AFP-derived peptides (e), AFP (f), CMV pp65-derived peptide (g) or tetanus toxoid protein (h). AFP and CMV pp65-derived peptides were tested in only HLA-A24 or A23 positive patients. Data are expressed as the mean + SD of specific spots.

**Table 5.** Characteristics of the patients with HLA-A24 or A23

|  | Patients treated by TAE (n = 16) | Patients treated by TAE with DC (n = 9) | p-value <sup>1</sup> |
|--|----------------------------------|---|----------------------|
| Age (years) <sup>2</sup>                                     | 65.7 $\pm$ 7.8                   | 67.8 $\pm$ 10.8                         | NS                   |
| Sex (M/F)  | 10/6                             | 7/2                                     | NS                   |
| ALT (IU/l)   | 55.9 $\pm$ 51.9                  | 75.4 $\pm$ 53.0                         | NS                   |
| Total bilirubin (g/dl)                                       | 1.4 $\pm$ 0.8                    | 1.4 $\pm$ 1.1                           | NS                   |
| Albumin (g/dl)   | 3.6 $\pm$ 0.7                    | 3.1 $\pm$ 0.6                           | NS                   |
| AFP level (ng/ml)  | 392.1 $\pm$ 877.8                | 337.2 $\pm$ 477.1                       | NS                   |
| Diff. degree of HCC (well/moderate or poor/ND <sup>3</sup> ) | 2/5/9                            | 3/3/3                                   | NS                   |
| Tumor size (small/large <sup>3</sup> )                       | 3/13                             | 0/9                                     | NS                   |
| Tumor multiplicity (multiple/solitary)                       | 15/1                             | 8/1                                     | NS                   |
| TNM stage (I, II/III, IV)                                    | 15/1                             | 7/2                                     | NS                   |
| Histology of nontumor liver (LC/chronic hepatitis)           | 13/3                             | 8/1                                     | NS                   |
| Liver function (Child A/B or C)                              | 10/6                             | 0/9                                     | 0.003                |
| Etiology (HCV/HBV/others)                                    | 11/1/4                           | 9/0/0                                   | NS                   |

<sup>1</sup>Abbreviations: NS, no statistical significance; ND, not determined. <sup>2</sup>Data are expressed as the mean  $\pm$  SD. <sup>3</sup>Small:  $\leq$ 2 cm, large:  $>$ 2 cm.

The precise mechanism of this phenomenon is still unknown; however, in recent studies, several treatments to destroy tumor cells by necrosis and/or apoptosis have induced antitumor immune responses in animal models<sup>14,44</sup> and even in humans.<sup>6-10</sup> In the study of *in situ* tumor ablation, it is reported that tumor ablation creates a tumor antigen source for the induction of antitumor immunity.<sup>9,44</sup> In another study regarding photodynamic therapy (PDT),<sup>45</sup> it is

reported that acute inflammation, expression of heat-shock proteins and providing tumor antigens to DCs caused by PDT induce tumor-specific immune responses.

Based on these results, we hypothesize that DC infusion with TAE can induce antitumor immune responses more effectively than TAE alone. According to DC research in recent years, successful enhancement of the antitumor immune response has been reported by intratumoral

**Table 6.** Enhancement of AFP-specific T cell response and treatment outcome


|            | Enhancement of AFP-specific T cell response | Recurrence, 3 months | Recurrence, 6 months |
|------------|---|----------------------|----------------------|
| Patient 1  | -   | N                    | U                    |
| Patient 2  | -   | N                    | M                    |
| Patient 4  | +   | M                    | ND                   |
| Patient 5  | -   | N                    | M                    |
| Patient 6  | +   | N                    | U                    |
| Patient 9  | -   | N                    | M                    |
| Patient 10 | -   | N                    | N                    |
| Patient 13 | -   | N                    | N                    |
| Patient 14 | -   | N                    | N                    |
| Patient 16 | -   | N                    | M                    |
| Patient 19 | -   | N                    | U                    |
| Patient 24 | +   | U                    | ND                   |
| Patient 25 | +   | M                    | ND                   |
| Patient 26 | +   | N                    | N                    |
| Patient 30 | +   | N                    | N                    |
| Patient 31 | +   | N                    | N                    |
| Patient 33 | -   | N                    | N                    |

Abbreviations: N, no recurrence; U, uninodular recurrence; M, multinodular recurrence; ND, not determined.

administration of DC in combination with tumor ablation.<sup>46,47</sup> Furthermore, immunotherapies using DC have been performed in patients with HCC and their antitumor effects are reported.<sup>48-50</sup> These results support our hypothesis and therefore, in the next step, we examined the immunological effects of DC infusion with TAE.

The comparison of frequency in patients who showed enhancement of AFP-specific immune responses revealed more frequency in patients with DC infusion than in those with TAE alone. On the other hand, there were no differences in the 2 groups in the comparison of frequency for patients who showed enhancement of CMV or TT-specific immune responses. These results suggest that DC infusion with TAE affects tumor-specific immune responses and that the effects are limited to the tumor area.

Some patients with TAE alone showed disappearance of AFP- or control antigen-specific T cells. Although the mechanism of this phenomenon is unknown, anticancer drugs used in TAE might suppress the immune responses, because most of the patients showed decreasing the number of lymphocytes after TAE. These results suggest that TAE alone might give a chance to enhance tumor-specific T-cell responses in only some patients. Further analysis using many more patients with TAE is necessary to make clear the differences in the patients with and without enhancement of T-cell responses. In contrast, disappearance of AFP- or control antigen-specific



**Figure 4.** Kinetics of AFP-specific T-cell responses determined by IFN- $\gamma$  ELISPOT assay before and after TAE. PBMCs were obtained before and 2-4 weeks and 3 months after TAE. Each graph indicates the kinetics of T cells specific for each antigen in each patient. Some patients received additional treatments as indicated in Tables 1 and 3 for a curative treatment after the measurement of T-cell responses at 2-4 weeks after TAE.

T cells was not observed in the patients with DC infusion, suggesting strong immunostimulating effect of this treatment.

In analysis of the association between the enhancement of AFP-specific T cells and clinical responses, no correlation could be shown, suggesting that enhancement of T-cell response associated with TAE or TAE with DC infusion may not have protective effect against HCC recurrence. To clarify the mechanism in more detail, we examined the kinetics of AFP-specific T-cell response. Increased frequency of AFP-specific T cells was transient and fell in 4 of 8 patients 3 months after treatment (Fig. 4). Similar to our results, Ayaru *et al.* also reported that the frequency of AFP-specific CD4<sup>+</sup> T cells fell in all patients by 1-3 months after TAE.<sup>8</sup> In addition, our results suggest that DC infusion with TAE is not effective to maintain the increased frequency of AFP-specific T cells.

Recent genome profiling studies of HCC show that HCC is a very heterogenous tumor.<sup>51</sup> Furthermore, HCC has multicentric carcinogenesis and develops at different time points. These characters of HCC may also be another reason for no correlation between the enhancement of AFP-specific T cells and clinical responses. The identification of many more tumor antigens and their T-cell epitopes is necessary for more precise analysis of the relationship between anti-tumor immune response and clinical response, and for immunotherapy.

In the recent study, it is reported that CD8<sup>+</sup> T-cell response to AFP is multispecific and AFP-specific IFN- $\gamma$ -producing CD8<sup>+</sup> T cells are directed against different epitopes spreading over the entire AFP sequence with no single

immuno-dominant CD8<sup>+</sup> T-cell epitope.<sup>52</sup> Therefore, there is a limitation to our study, because the number of immunogenic AFP-derived peptides applicable in this study is small. However, the results of the present study suggest that TAE with DC infusion enhances the tumor-specific immune responses. Although these modified immune responses may not be sufficient to prevent HCC recurrence because the

enhanced immune responses are transient and attenuate within 3 months, these results may contribute to the development of novel immunotherapeutic approach for HCC.

#### Acknowledgements

The authors thank Ms. Maki Kawamura and Ms. Kazumi Fushimi for technical assistance and for their invaluable help with sample collection.

#### References

- Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. *Ann Surg* 2000;232:381-91.
- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693-9.
- Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. *Oncology* 1998;55:39-47.
- Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). *J Gastroenterol* 2008;43:18-26.
- Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. *J Gastroenterol* 2008;43:71-8.
- Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. *Cancer Res* 2001;61:192-6.
- Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai K, Yamashita T, Yokoyama K, Mukaida N, Matsushima K, Matsui O, Kaneko S. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. *Clin Exp Immunol* 2007;147:296-305.
- Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. *J Immunol* 2007;178:1914-22.
- Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C, Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. *Cancer Res* 2006;66:1139-46.
- Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. *Int J Cancer* 2006;118:1194-204.
- Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. *Br J Cancer* 2003;88:1772-9.
- Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. *Lasers Surg Med* 2006;38:509-15.
- Yamamoto N, Homma S, Sery TW, Donoso LA, Hooper JK. Photodynamic immunopotential: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. *Eur J Cancer* 1991;27:467-71.
- den Brok MH, Suttmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. *Cancer Res* 2004;64:4024-9.
- Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. *Cancer Res* 2001;61:8105-9.
- Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. *J Exp Med* 2000;191:423-34.
- Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. *Cancer Res* 2005;65:1018-26.
- Takayasu K, Arai S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* 2006;131:461-9.
- Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. *Radiology* 1993;188:79-83.
- Yamada R, Kishi K, Sonomura T, Tsuda M, Nomura S, Satoh M. Transcatheter arterial embolization in unresectable hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 1990;13:135-9.
- Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *J Hepatol* 1990;11:181-4.
- Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. *N Engl J Med* 1995;332:1256-61.
- Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology* 1998;27:1578-83.
- Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002;359:1734-9.
- Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002;35:1164-71.
- Hsu HC, Wei TC, Tsang YM, Wu MZ, Lin YH, Chuang SM. Histologic assessment of resected hepatocellular carcinoma after

- transcatheter hepatic arterial embolization. *Cancer* 1986;57:1184-91.
27. Kenji J, Hyodo I, Tanimizu M, Tanada M, Nishikawa Y, Hosokawa Y, Mandai K, Moriwaki S. Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases. *Semin Oncol* 1997;24: S6-71-S6-80.
  28. Kobayashi N, Ishii M, Ueno Y, Kisara N, Chida N, Iwasaki T, Toyota T. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. *Liver* 1999;19:25-31.
  29. Xiao EH, Li JQ, Huang JF. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. *World J Gastroenterol* 2004;10:190-4.
  30. Kanai M, Kohda H, Sekiya C, Namiki M. Effects on interleukin 1 alpha and beta production of peripheral blood mononuclear cells from patients with hepatocellular carcinoma after transcatheter arterial embolization. *Gastroenterol Jpn* 1990;25:662.
  31. Yamazaki H, Nishimoto N, Oi H, Matsushita M, Ogata A, Shima Y, Inoue T, Tang JT, Yoshizaki K, Kishimoto T, Inoue T. Serum interleukin 6 as a predictor of the therapeutic effect and adverse reactions after transcatheter arterial embolization. *Cytokine* 1995;7:191-5.
  32. Itoh Y, Okanoue T, Ohnishi N, Nishioji K, Sakamoto S, Nagao Y, Nakamura H, Kirishima T, Kashima K. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. *Liver* 1999;19:97-103.
  33. Araki T, Itai Y, Furui S, Tasaka A. Dynamic CT densitometry of hepatic tumors. *AJR Am J Roentgenol* 1980;135: 1037-43.
  34. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002. 81.
  35. Terayama N, Miyayama S, Tatsu H, Yamamoto T, Toya D, Tanaka N, Mitsui T, Miura S, Fujisawa M, Kifune K, Matsui O, Takashima T. Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. *J Vasc Interv Radiol* 1998;9:501-8.
  36. Okamoto H, Shin J, Mion S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. *Jpn J Microbiol* 1967;11: 323-36.
  37. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. *Cancer Res* 2003; 63:4112-8.
  38. Japan LCSG. Classification of primary liver cancer. English edn. 2. Tokyo: Kanehara, 1997.
  39. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 1994;19:1513-20.
  40. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. *Hepatology* 2006;43:1284-94.
  41. Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. *J Hepatol* 2008;49:946-54.
  42. Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, Takiguchi M. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. *J Immunol* 1997;159: 6242-52.
  43. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A\*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. *Blood* 2001;98:1872-81.
  44. Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, Voll R, Strobel D, Hahn EG, Schuppan D. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. *Cancer Res* 2003;63: 6496-500.
  45. Korbelik M, Kros J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. *Cancer Res* 1996;56: 5647-52.
  46. Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, Toda M, Azuma I, Iwai T, Kawakami Y. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. *Clin Cancer Res* 2006;12: 7465-75.
  47. Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzevoval E, Eisenbach L. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. *Clin Cancer Res* 2005;11: 4955-61.
  48. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. *J Gastroenterol Hepatol* 2002;17: 889-96.
  49. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K, Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. *Cancer Immunol Immunother* 2003; 52:155-61.
  50. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. *J Immunother* 2005;28: 496-504.
  51. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. *Gastroenterology* 2004; 127:S51-5.
  52. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowicz F, Obermaier R, Hopt UT, Blum HE, Spangenberg HC. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. *Hepatology* 2008;48:1821-33.

## Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma

Masanori Kawano MD, Hideji Nishida MD, PhD,  
Yasunari Nakamoto MD, PhD, Hiroshi Tsumura MD, PhD,  
Hiroyuki Tsuchiya MD, PhD

Received: 20 February 2009 / Accepted: 1 March 2010 / Published online: 16 March 2010  
© The Association of Bone and Joint Surgeons® 2010

### Abstract

**Background** We previously reported a limb-salvage technique by treating tumor-bearing bone with liquid nitrogen. We also reported systemic antitumor immunity was enhanced by cryotreatment in a murine osteosarcoma (LM8) model. We therefore combined the cryotreatment of tumor with dendritic cells to promote tumor-specific immune responses.

**Questions/purposes** We determined whether our technique could enhance systemic immune response and inhibit metastatic tumor growth in a murine osteosarcoma model. **Materials and Methods** To evaluate activation of the immune response, we prepared six groups of C3H mice (80 mice total): (1) excision only, (2) dendritic cells without

reimplantation of the cryotreated primary tumor, (3) reimplantation of the cryotreated primary tumor alone, (4) dendritic cells combined with reimplantation of the cryotreated primary tumor, (5) dendritic cells exposed to cryotreated tumor lysates without reimplantation of the cryotreated primary tumor, and (6) dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor. We then compared and verified the activation state of each group's antitumor immunity. **Results** Mice that received dendritic cells exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor group had high serum interferon  $\gamma$ , reduced pulmonary metastases, and increased numbers of CD8(+) T lymphocytes in the metastatic areas.

**Conclusions** Combining tumor cryotreatment with dendritic cells enhanced systemic immune responses and inhibited metastatic tumor growth.

**Clinical Relevance** We suggest immunotherapy could be developed further to improve the treatment of osteosarcoma.

Each author certifies that he or she has no commercial associations that might pose a conflict of interest in connection with the submitted article.

Each author certifies that his or her institution has approved the animal protocol for this investigation, and that all investigations were conducted in conformity with ethical principles of research.

This work was performed at the Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, and the Department of Orthopaedic Surgery, Faculty of Medicine, Oita University.

M. Kawano, H. Nishida, H. Tsuchiya (✉)  
Department of Orthopaedic Surgery, Graduate School of  
Medical Science, Kanazawa University, 13-1 Takara-machi,  
Kanazawa 920-8641, Japan  
e-mail: tsuchi@med.kanazawa-u.ac.jp

M. Kawano, H. Tsumura  
Department of Orthopaedics Surgery, Faculty of Medicine,  
Oita University, Oita, Japan

Y. Nakamoto  
Department of Gastroenterology, Graduate School of Medical  
Science, Kanazawa University, Kanazawa, Japan

### Introduction

The standard treatment of osteosarcoma consists of pre-operative chemotherapy, surgical tumor excision, and postoperative chemotherapy. Limb-saving surgery is feasible in most cases. Advances in osteosarcoma treatment have now achieved a 5-year survival rate of 60% to 90% for patients, and limb function after reconstruction continues to improve with time [3, 16, 30, 46, 47, 49].

Tsuchiya et al. developed a new approach using frozen autografts [48] to improve reconstruction after osteosarcoma resection. The tumor is resected with an adequate margin, and the resected specimen is immersed in liquid

nitrogen for 20 minutes to kill all tumor cells. After thawing, the specimen is returned to the original place with appropriate internal fixation to reconstruct the defect. Compared with heat-treated bones [8, 14], bone genetic proteins and native biomechanical structures are preserved after cryotreatment [53]. In one report limb function using the technique of Tsuchiya et al. was rated as excellent in 71.4% of patients, and good in 10.7%, as assessed by the functional evaluation system of Enneking [11]. Two studies suggest the approach enhanced bone formation when compared histologically with pasteurized bone and irradiated bone [43, 48]. Another advantage in reimplanting cryotreated tumor tissue is its effect on the immune system [50]: tumor tissue after cryoablation *in situ* provokes an immune reaction in patients with breast and prostate cancer [6, 8, 39]. Brewer et al. reported metastatic tumors sometimes disappear or shrink after *in situ* cryoablation of the primary tumor with liquid nitrogen [4]. The structure of tumor antigens is retained in frozen tumor, and leukocytes probably can recognize these antigens. Similar antitumor effects can be expected from our reconstructive procedure of reimplanting tumor-bearing bone after cryotreatment with liquid nitrogen.

Nishida et al. observed an inadequate antitumor effect after reimplantation of frozen tumor tissue alone [35]. However, the antitumor effect was enhanced by promoting nonspecific immune activation by intraperitoneal injection of OK-432, a substance extracted from *alpha-Streptococcus pyogenes*. This approach promotes inflammation and activation of dendritic cells (DCs) that initiate the specific antitumor effect [19]. This type of immunotherapy reportedly is effective for breast and prostate cancers [6, 8, 39]. Many groups have reported successful immunotherapy for osteosarcoma [5, 15, 18, 20, 22, 24, 25, 33, 34, 36, 42, 51, 52]. However, the ability to control metastatic lesions and local recurrence does not appear to be superior to other adjuvant treatments [2, 7, 13, 23, 29].

We therefore wondered whether combining cryotreatment and immunotherapy might enhance tumor response. We specifically determined whether: (1) antitumor immunity could be enhanced through activation and transfer of DCs combined with reimplantation of the cryotreated primary tumor, and (2) metastatic lesions could be prevented owing to the involvement of T lymphocytes in a murine osteosarcoma model (LM8).


## Materials and Methods

Using a reported method to induce osteosarcoma [1, 35], we hypodermically implanted  $1 \times 10^6$  LM8 cells (a murine osteosarcoma cell line) into the subcutaneous gluteal region of 80 female C3H mice, 6 to 8 weeks old. Tumors

developed in all animals. Two weeks after inoculation, we surgically excised the tumors and cryotreated them with liquid nitrogen. We established the following six groups (Fig. 1): (1) the tumor was excised with wide margins 14 days after inoculation ( $n = 15$ ); (2) the tumor was excised with wide margins 14 days after inoculation and bone marrow-derived DCs then were injected into the contralateral subcutaneous gluteal region without reimplantation of the cryotreated primary tumor twice a week ( $n = 15$ ); (3) the tumor was excised with wide margins 14 days after inoculation and reimplanted after cryotreatment with liquid nitrogen into the contralateral gluteal region to evaluate for local recurrence from frozen tumor tissue ( $n = 15$ ); (4) the tumor was excised 14 days after inoculation and reimplanted after cryotreatment into the contralateral gluteal region to evaluate for local recurrence, and DCs then were injected twice a week into this secondary site ( $n = 15$ ); (5) the tumor was excised with wide margins 14 days after inoculation and DCs exposed to cryotreated tumor lysates were injected twice a week into the contralateral gluteal region without reimplantation of the cryotreated primary tumor ( $n = 15$ ); and (6) the tumor was excised with wide margins 14 days after inoculation and reimplanted after the treatment with liquid nitrogen into the contralateral gluteal region to evaluate for local recurrence (same as Group 3) with the addition of DCs exposed to cryotreated tumor lysates injected twice a week ( $n = 15$ ). We harvested tumor from 30 mice, and then the tumor was treated with liquid nitrogen to create the lysates. We presumed a systemic immune response would be induced by injecting DCs around the frozen tumor tissue. We microscopically determined the presence of metastases in the lungs 2 weeks after the tumor inoculation. We had previously confirmed the presence of pulmonary metastases in an additional 20 mice in a preliminary experiment in advance. We also confirmed that there were no viable cells after cryotreatment using liquid nitrogen, in agreement with a previous study [35]. We observed no recurrence of the tumor at the primary site of inoculation after excision. All experiments were performed under the guidelines for animal experiments as stipulated by the Kanazawa University Graduate School of Medical Science [37].

LM8 cells, derived from Dunn osteosarcoma, were provided by the Riken BioResource Center (Saitama, Japan). The cells were maintained in complete medium consisting of RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100  $\mu$ g streptomycin per mL, and 100 units penicillin per mL and were cultured at 37°C in 5% CO<sub>2</sub>. To establish local implantation of the tumor and subsequent lung metastasis, the LM8 cells ( $1 \times 10^6$ ) were suspended in 0.2 mL phosphate-buffered saline (PBS) and subcutaneously inoculated into the right





**Fig. 1** A diagram of the experimental protocol and treatment schedule is shown. Two weeks after tumor inoculation, tumors were treated by one of the following methods: (1) excision only ( $n = 15$ ); (2) DCs without reimplantation of the cryotreated primary tumor ( $n = 15$ ); (3) reimplantation of the cryotreated primary tumor ( $n = 15$ ); (4) DCs pulsed with cryotreated tumor lysates and

reimplantation of the cryotreated primary tumor ( $n = 15$ ); (5) DCs pulsed with cryotreated tumor lysates without reimplantation of the cryotreated primary tumor ( $n = 15$ ); or (6) DCs pulsed with cryotreated tumor and reimplantation of the cryotreated primary tumor (LN) ( $n = 15$ ). The mice were euthanized and evaluated 6 weeks after tumor inoculation. sc = subcutaneous.

gluteal region of the mice. All animals had macroscopically and microscopically confirmed lung metastases within 4 weeks [1].

C3H mice were purchased from Sankyo Labo Inc (Toyama, Japan) and housed in a specific pathogen-free animal facility in our laboratory. We were not able to accurately determine the survival time of each group because the guidelines for animal experiments concerning pain required euthanasia in distressed animals.

Liquid nitrogen ( $-196^{\circ}\text{C}$ ) was used for cryotreatment. Tumor tissue was collected on gauze and soaked in liquid nitrogen for 20 minutes for en bloc tumor tissue freezing. The tumor was prethawed at room temperature ( $20^{\circ}\text{C}$ ) for 15 minutes and then thawed in distilled water ( $20^{\circ}\text{C}$ ) for 15 minutes. The liquid nitrogen-treated tumor tissue

was transplanted subcutaneously in the left gluteal region of the same mouse.

Because the mice were genetically identical, the structure of the major histocompatibility complex (MHC) Class I molecules was such that the T cells would be able to recognize the MHC Class I with antigens on the antigen-presenting cells (APCs) [17, 27]. Bone marrow-derived DCs were generated as described by Lutz and Rössner [28] with minor modifications. Briefly, erythrocyte-depleted mouse bone marrow cells obtained from flushed marrow cavities ( $1 \times 10^6$  cells/mL) were cultured in complete medium with 20 ng/mL recombinant mouse GM-CSF (PeproTech EC Ltd, London, UK) in 10-cm tissue culture dishes at  $37^{\circ}\text{C}$  in an atmosphere containing 50 mL  $\text{CO}_2$  per L. On Days 3 and 6, half of the medium was added to the

same volume of fresh complete medium and used to replenish the original plates. The freeze-thawed tumor lysate was added to the DC cultures on Day 6 at a ratio of five DC equivalents to one tumor cell (ie, 5:1) and incubated at 37°C in an atmosphere containing 50 mL CO<sub>2</sub> per L. After 24 hours of incubation, nonadherent cells including DCs were harvested by gentle pipetting.

For fluorescence activated cell sorting (FACS) analysis, DCs were counted with a FACSCalibur<sup>™</sup> Flow Cytometer (Becton-Dickinson, San Jose, CA) and stained with fluorochrome-conjugated antibodies (BD Pharmingen, Tokyo, Japan) for the following markers: cluster of differentiation (CD)11c, CD80, CD86, I-Ad, and CD40. CD11c was used as a marker for all DCs regardless of the degree of maturation, whereas CD80, CD86, I-Ad, and CD40 are markers for DCs. Data analysis was performed with CELLQuest<sup>™</sup> software (Becton-Dickinson). The corresponding labeled isotype antibodies served as controls. DCs used for vaccination were washed twice, enumerated, and resuspended in PBS at  $1 \times 10^6$ /mL.

We inoculated LM8 cells ( $5 \times 10^6$ ) in a mouse to make the tumor lysate. After 4 weeks, we resected the tumor mass and soaked the entire tumor in liquid nitrogen to kill the tumor cells. We mixed cryonecrotic tissue with DCs at Culture Day 6, after the tumor was defrosted, and the homogenate was prepared using PBS. The homogenate was passed through a 0.2- $\mu$ m filter to remove bacteria and tissues and mixed with the DCs for 24 hours.

After intraperitoneal injection of 5 mL sodium pentobarbital (Somnopentyl<sup>®</sup>; Kyontsu Seiyaku, Tokyo, Japan), mice were euthanized by cervical dislocation and their blood was collected. Murine interferon (IFN)- $\gamma$  and interleukin (IL)-4 release were measured by ELISA using Quantikine<sup>®</sup> (R & D Systems, Minneapolis, MN) according to the manufacturer's protocol using an Easy Reader EAR340 microtest plate reader (SLT-Labinstruments, Salzburg, Austria).

We estimated the area of the pulmonary metastatic lesion on 50 serial histologic sections of each lung by manually drawing orthogonal lines delimiting the edges of the pulmonary metastatic lesion and selected the widest part of the specimen. The area was determined by multiplying the maximum orthogonal dimensions using ImageJ software (NIH, Bethesda, MD; <http://rsb.info.nih.gov/ij/>). We compared the mean areas between the six groups.

For immunohistochemistry, lung specimens were fixed in 20% formalin and embedded in paraffin. For each case, we examined all the blocks of lung tissues of formalin-fixed, paraffin-embedded tumor tissue. All specimens were decalcified, although we found the decalcification step did not influence the immunohistochemistry for any of the stains. Five sections for each mouse were cut 4- $\mu$ m thick. Each section was cut at the maximum diameter.

CD8(+) T lymphocytes and natural killer (NK) cells in the pulmonary metastatic lesion were quantified by measuring the immunohistochemistry-positive cells per unit area in each group. Rehydrated tissue sections were incubated with rat monoclonal antibody raised against CD8(+) T lymphocytes of mouse origin (Santa Cruz Biotechnology, Santa Cruz, CA) and rat monoclonal antibody raised against NK cells of mouse origin (Abcam Plc, Cambridge, UK). The two antibodies were diluted 1:50 with PBS. Color reactions were performed at room temperature for 15 minutes and cover slips were mounted with glycerol and gelatin.

We determined differences in serum IFN- $\gamma$ , serum IL-4, pulmonary metastatic area, and number of CD8(+) lymphocytes and NK cells in the metastatic area among the six groups using a nonrepeated-measures ANOVA and the Scheffe test. All analyses were conducted with SPSS<sup>®</sup> 11.0 software (SPSS Japan Inc, Tokyo, Japan).

## Results

We activated antitumor immunity by combining DCs exposed to lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor. On Culture Day 7, the ratio of mature DCs to immature DCs was increased compared with the ratio at Culture Day 6 (Fig. 2; immature DCs, upper left; mature DCs, upper right). Moreover, this increase was more apparent in groups incubated with tumor lysate. Serum IFN- $\gamma$  levels were greater ( $p < 0.0001$ ) in the mice that received DCs combined with reimplantation of the cryotreated primary tumor ( $119.0 \pm 7.61$  pg/mL) than in the cryotreated primary tumor alone group ( $37.33 \pm 2.58$  pg/mL). Moreover, the group that received tumor lysate-exposed DCs combined with reimplantation of the cryotreated primary tumor ( $157.33 \pm 14$  pg/mL) had a greater ( $p < 0.0001$ ) IFN- $\gamma$  level than the group that received only tumor lysate-exposed DCs without reimplantation of the cryotreated primary tumor ( $120.27 \pm 11.29$  pg/mL) (Fig. 3). Serum IL-4 was lower ( $p < 0.0001$ ) in the mice that received DCs exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor group ( $13.33 \pm 9.75$  pg/mL) than in the excision-only group ( $45.06 \pm 5.71$  pg/mL) (Fig. 4).

The enhanced immune response by T lymphocytes reduced metastatic lesions. Reduction of the metastatic area was greater ( $p < 0.0001$ ) in the group that received DCs without reimplantation of the cryotreated primary tumor ( $15.99 \pm 3.93$  mm<sup>2</sup>) than in the excision-only group ( $24.12 \pm 3.60$  mm<sup>2</sup>). The reduction of the metastatic area was greater ( $p < 0.0001$ ) in the DCs combined with reimplantation of the cryotreated primary tumor group ( $5.39 \pm 1.49$  mm<sup>2</sup>) than in the reimplantation of






Fig. 2A–C DC activation status was examined using flow cytometry. DCs at Culture Day 7 (Group B) were more mature than DCs at Culture Day 6 (Group A). On Culture Day 7, DC maturity was

greatest in the groups receiving lysate-primed DCs (Group C) than in those not receiving lysate-primed DCs (Group B).


Fig. 3 A graph of the serum IFN- $\gamma$  levels in the six treatment groups is shown. The samples were collected 28 days after the reimplantation (surgery) and/or DC adoptive transfer. Mice that received DCs exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor group showed a highest IFN- $\gamma$  level. Error bars represent SD.



**Fig. 4** A graph of the serum IL-4 in the six treatment groups is shown. Sera were collected 28 days after the reimplantation surgery and/or DC adoptive transfer. DCs exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor group showed a lower level than any of the other groups. Error bars represent SD.




**Fig. 5** Reduction of the metastatic area in the six treatment groups is shown. The samples were gathered 28 days after the reimplantation surgery and/or DC adoptive transfer. Error bars represent SD.



the cryotreated primary tumor alone group ( $13.22 \pm 2.59 \text{ mm}^2$ ) (Fig. 5). CD8(+) T lymphocytes gathered in the pulmonary metastatic area in DC-treated groups, however, NK cells were not recruited to the metastatic area in the DC-treated groups compared with the nonDC-treated groups (Fig. 6). The number of CD8(+) T lymphocytes per unit area was greater ( $p < 0.0001$ ) in the DCs combined with reimplantation of the cryotreated primary tumor group ( $8.33 \pm 2.57 \text{ cells/mm}^2$ ) than in the reimplantation of the cryotreated primary tumor alone group ( $2.44 \pm 0.53 \text{ cells/mm}^2$ ). Mice that received DCs exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor ( $12.79 \pm 2.14$


$\text{cells/mm}^2$ ) showed higher ( $p < 0.0001$ ) levels than the group that received DCs exposed to the lysates of cryotreated tumor without reimplantation of the cryotreated primary tumor ( $8.71 \pm 2.39 \text{ cells/mm}^2$ ) (Fig. 7). The number of NK cells per unit area was greater ( $p < 0.0001$ ) in the group that received DCs exposed to the lysates of cryotreated tumor without reimplantation of the cryotreated primary tumor ( $3.90 \pm 2.17 \text{ cells/mm}^2$ ) than in the excision-only group ( $1.20 \pm 0.30 \text{ cells/mm}^2$ ) (Fig. 8). The CD8(+) T lymphocyte, CD4(+) T lymphocyte, and DC infiltrations in reimplanted tumors were similar to those seen with pulmonary metastases (data not shown).



**Fig. 6A–I.** To evaluate CD8(+) T lymphocytes and NK cells in pulmonary metastasis, immunostaining was performed: (A) CD8(+) T lymphocytes in Group 1, (B) CD8(+) T lymphocytes in Group 2, (C) CD8(+) T lymphocytes in Group 3, (D) CD8(+) T lymphocytes in Group 4, (E) CD8(+) T lymphocytes in Group 5, (F) CD8(+) T lymphocytes in Group 6, (G) NK cells in Group 1, (H) NK cells in

Group 2, (I) NK cells in Group 3, (J) NK cells in Group 4, (K) NK cells in Group 5, and (L) NK cells in Group 6. CD8(+) T lymphocytes gathered in Groups D,E, and F. However, they did not gather in Groups A, B, and C. However, NK cells were recruited only in Groups A, B, and C. (Original magnification,  $\times 2000$ ).

**Fig. 7** The numbers of CD8(+) T lymphocytes per unit area in the six treatment groups are shown. The samples were gathered 28 days after the reimplantation surgery and/or DC adoptive transfer. DCs exposed to the lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor group showed a higher level than any other groups. Error bars represent SD.




**Discussion**

Various immunotherapies for osteosarcoma have been tried. As standard treatments for osteosarcoma are ineffectual for many patients, new treatments need to be developed. In the 1970s, immunotherapy for osteosarcoma was reported by Southam et al. [42], Neff and Enneking [34], and Campbell et al. [5]. In the 1980s, new methods such as the use of interferons and Bacille de Calmette et Guérin were reported [22, 24, 36]. Another approach used antiidiotypic antibodies using T cells and liposome encapsulation [18, 51, 52]. Current methods of

immunotherapy for osteosarcoma include peptide therapy or gene transfer therapy combined with hyperthermia therapy [10, 15, 21, 25, 33]. We asked whether (1) anti-tumor immunity could be achieved through activation of DCs combined with reimplantation of the cryotreated primary tumor and (2) if metastatic lesions would be prevented owing to enhanced T lymphocyte involvement.

We acknowledge limitations in this study. First, we used mice with an identical genetic makeup. The structure of the MHC Class I molecules was similar and the T cells could recognize the MHC Class I. However, we needed to use DCs from a different (albeit genetically identical) mouse to

**Fig. 8** The numbers of NK cells per unit area in the six treatment groups are shown. The samples were gathered 28 days after the reimplantation surgery and/or DC adoptive transfer. Error bars represent SD.



accomplish our adoptive transfer experiments. We minimized the potential for an immune response to nonself antigens by using genetically identical tumor tissue and mice. It would be necessary to use DCs derived from the same individual in clinical application, but this could not be achieved in our mouse model. In humans, however, monocytes are separated from the patient's own peripheral blood and DCs can be induced from these monocytes. Second, we could not completely replicate the clinical approach used in humans in our mouse model. In clinical cases frozen bone always is returned to the same site. However, it was impossible to replicate this in our experimental mouse model in which transplanted tumor cells were removed from the tibia and then returned to the same place after cryotreatment. In a preliminary experiment we attempted to do just that and these 20 mice could not move and died of starvation. We therefore used the contralateral gluteal region to check for local recurrence after tumor excision or recurrence from frozen tissue.

Antitumor immunity appeared to be activated through DCs combined with reimplantation of the cryotreated primary tumor or by exposing the transferred DC to lysates of cryotreated tumor. The use of lymphokine-activated killer (LAK) therapy has been used with other types of tumors [26]. However, T lymphocytes, which are the effectors, do not accumulate inside osteosarcoma tumors as expected. Autoclaving supplemented by DCs is thought to enhance the antitumor effect, but hyperthermia causes proteins to denature, and activation of the antitumor effect is often insufficient [37]. Several studies [12, 31, 41] report peptide vaccine therapy, but many patients apparently develop immunotolerance [45]. Thus, immunotherapy for malignant tumor achieved by these various methods has not been established definitively although investigations continue to try to overcome the major hurdles associated with immunotherapy (Table 1). We emphasize the immune response is activated by cryotreatment but not by heat-treated tissue.

Our method differs from those described by others [7, 9, 10, 14]. In some regards DCs are believed to be the principal APCs for initiating immune responses *in vivo* [32]. In comparison with other traditional adjunct therapeutic options for cancer, such as radiation therapy and chemotherapy, immunotherapy provides a more targeted treatment to the cancer, with potentially fewer detrimental effects on noncancerous cells [30, 40]. DCs without sufficient cancer antigens may not have the ability to kill tumor cells and present the antigen to T lymphocytes by themselves. Our data suggest the antitumor effect in the group that received DCs without reimplantation of cryotreated primary tumor was almost the same as that in the reimplantation of cryotreated primary tumor alone group. The data further suggest the effects increased only when exposing the DCs to tumor lysates in the absence of cryonecrotic primary tumors. However, combining reimplantation of cryotreated primary tumor and DCs exposed to cryotreated tumor lysates produced synergistic effects. Using reimplantation of cryotreated primary tumor is more appropriate for clinical applications. We therefore believe an efficient immune response will be activated when DCs recognize tumor antigens appropriately. CD8(+) T cells act as an effector by the Th1 route, and this is promoted mainly by IFN- $\gamma$  and IL-12 [38]. However, IL-4 [21], IL-6, and IL-10 strengthen humoral immunity. Levels of IFN- $\gamma$ , IL-2, and IL-12 generally increase when cell-mediated immunity is activated, and IL-4, IL-6, and IL-10 increase when humoral immunity is activated. These cytokines act in opposition to maintain an immune balance.

Our data suggest enhanced T lymphocyte recruitment and function reduce metastatic lesions in a murine osteosarcoma model. Immunoreactivity increased slightly in mice that received DCs exposed to lysates of cryotreated tumor combined with reimplantation of the cryotreated primary tumor. NK cells attack the tumor independently of APCs. NK cells attack cells that downregulate MHC Class

Table 1. Immunotherapeutic trials of malignant tumors

| Tumor                       | Immune intervention                                      | Route  | Immunologic response | Comments   | References   |
|-----------------------------|--|--------|----------------------|--|--------------|
| Osteosarcoma                | BCG  | SC     | NC                   | No consistent clinical effect  | [22, 24]     |
| Osteosarcoma                | Interferon $\alpha$                                      | SC, IV | PR-NC                | Osteosarcoma-associated antigens have potential for targeted immunotherapy                                       | [36]         |
| Unknown                     | LAK  | IV     | NC                   | T lymphocytes were unable to penetrate the tumor   | [26]         |
| Osteosarcoma                | Antiidiotypic antibodies                                 | IV     | NC                   | It may be possible to circumvent this heterogeneity by activation of tissue macrophages to the tumoricidal state | [18, 51, 52] |
| Breast cancer, osteosarcoma | Peptide therapy combined with hyperthermia therapy       | SC, IV | NC                   | It may be a potential agent for use in immunotherapy   | [15, 20]     |
| Osteosarcoma                | Gene transfer therapy combined with hyperthermia therapy | IV     | NC                   | IL-23 seems to be a less effective immunotherapeutic for adjuvant treatment of osteosarcomas                     | [25, 33]     |
| Unknown                     | Peptide vaccine therapy                                  | SC     | NC-PD                | Many patients have peptide-induced tolerance develop   | [45]         |
| Osteosarcoma                | Cryoimmunology and DCs                                   | SC     | PR                   | Combining cryotreatment with DCs resulted in enhanced antitumor effects  | Our data     |

BCG = Bacille de Calmette et Guérin; SC = subcutaneous; NC = no change; IV = intravenous; PR = partial response; LAK = lymphokine-activated killer; IL = interleukin; PD = progressive disease; DCs = dendritic cells.

I expression or have a stressed appearance [44]. We observed a reduced tumor burden in the groups that received transplanted DCs, which correlated with recruitment of CD8 lymphocytes to the tumor site as observed with immunohistochemistry.

Returning the frozen bone after liquid nitrogen treatment to its original place can be readily used in the clinic. After the first cryotreatment, it is possible to perform the treatment again using cultured DCs if a patient's tumor cells have been preserved. This approach therefore still can be used even after other methods (such as chemotherapy, radiation therapy, or surgery) no longer are reasonable. Combining DCs pulsed with lysates of cryotreated tumor and reimplantation of the cryotreated primary tumor enhanced antitumor effects. We believe the approach may be a useful alternative for patients with osteosarcoma when other treatment options including chemotherapy, radiotherapy, and surgical treatment have been ineffective.

**Acknowledgments** We thank Katsuro Tomita, Akihiko Takeuchi, Shuichi Kaneko, and Yohei Marukawa for supervision in this study.

## References

- Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. *Int J Cancer*. 1998;76:418-422.
- Bacci G, Lari S. Adjuvant and neoadjuvant chemotherapy in osteosarcoma. *Chir Organi Mov*. 2001;86:253-268.
- Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol*. 2002;20:776-790.
- Brewer WH, Austin RS, Capps GW, Neifeld JP. Intraoperative monitoring and postoperative imaging of hepatic cryosurgery. *Semin Surg Oncol*. 1998;14:129-155.
- Campbell CJ, Cohen J, Enneking WF. Editorial: New therapies for osteogenic sarcoma. *J Bone Joint Surg Am*. 1975;57:143-144.
- Chin JL, Lim D, Abdelhady M. Review of primary and salvage cryo-ablation for prostate cancer. *Cancer Control*. 2007;14:231-237.
- DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, Suit HD. Radiotherapy for local control of osteosarcoma. *Int J Radiat Oncol Biol Phys*. 2005;61:492-498.
- de Moraes AM, Pavarin LB, Herreros F, de Aguiar Michelman F, Velho PE, de Souza EM. Cryosurgical treatment of lentigo maligna. *J Dtsch Dermatol Ges*. 2007;5:477-480.
- Dinçbaşı FO, Koca S, Mandel NM, Hiz M, Dervişoğlu S, Seçmezacar H, Oksüz DC, Ceylaner B, Uzel B. The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. *Int J Radiat Oncol Biol Phys*. 2005;62:820-828.
- Duparc J, Massin P, Bocquet L, Benfrech E, Cavagna R. [Autoclaved tumoral autografts: apropos of 12 cases, 6 of which highly malignant] [in French]. *Rev Chir Orthop Reparatrice Appar Mot*. 1993;79:261-271.
- Enneking WF. A system for functional evaluation of the surgical management of musculoskeletal tumors. In: Enneking WF, ed. *Limb Salvage in Musculoskeletal Oncology*. New York, NY: Churchill-Livingstone; 1987:5-16.
- Enomoto Y, Bharti A, Khaleque AA, Song B, Liu C, Apostolopoulos V, Xing PX, Calderwood SK, Gong J. Enhanced immunogenicity of heat shock protein 70 peptide complexes from

- dendritic cell-tumor fusion cells. *J Immunol.* 2006;177:5946–5955.
13. Fagioli F, Biasini E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E. Poor prognosis osteosarcoma: new therapeutic approach. *Bone Marrow Transplant.* 2008;41(suppl 2): S131–S134.
  14. Harrington KD. The use of hemipelvic allografts or autoclaved grafts for reconstruction after wide resections of malignant tumors of the pelvis. *J Bone Joint Surg Am.* 1992;74:331–341.
  15. Herbert LM, Grosso JF, Dorsey M Jr, Fu T, Keydar I, Cejas MA, Wreschner DH, Smorodinski N, Lopez DM. A unique mucin immunoenhancing peptide with antitumor properties. *Cancer Res.* 2004;64:8077–8084.
  16. Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB. Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. *Clin Orthop Relat Res.* 2008;466:1292–1301.
  17. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikchara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med.* 1992;176:1693–1702.
  18. Killion JJ, Fidler IJ. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. *Immunomethods.* 1994;4:273–279.
  19. Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. *J Immunol.* 2007;178:613–622.
  20. Kubista B, Trieb K, Blahovec H, Kotz R, Micksche M. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis. *Anticancer Res.* 2002;22:789–792.
  21. Kumaratilake LM, Ferrante A. IL-4 inhibits macrophage-mediated killing of *Plasmodium falciparum* in vitro: a possible parasite-immune evasion mechanism. *J Immunol.* 1992;149:194–199.
  22. Larsson SE, Lorentzon R, Boquist L. Immunotherapy with irradiated tumour cells and BCG in experimental osteosarcoma. *Acta Orthop Scand.* 1981;52:469–474.
  23. Lee JW, Kim H, Kang HJ, Kim HS, Park SH, Kim IO, Ahn HS, Shin HY. Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation. *Cancer Res Treat.* 2008;40: 172–177.
  24. Leventhal BG. Immunotherapy of sarcomas. *Natl Cancer Inst Monogr.* 1981;56:183–187.
  25. Liebau C, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Merk H, Wolfram N, Baltzer AW. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. *Anticancer Res.* 2004;24:2861–2867.
  26. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. *J Immunol.* 1980;125:1487–1493.
  27. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods.* 1999;223:77–92.
  28. Lutz MB, Rössner S. Factors influencing the generation of murine dendritic cells from bone marrow: the special role of fetal calf serum. *Immunobiology.* 2007;212:855–862.
  29. Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV, Ryjkov AD, Tepliakov VV, Bokhian BY, Glebovskaya VV. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. *Mayo Clin Proc.* 2003;78:147–155.
  30. Meyers PA, Schwartz CL, Krailo M, Kleincerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvoos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol.* 2005; 23:2004–2011.
  31. Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, Kieber-Emmons T. Pre-clinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. *Vaccine.* 2007;25:3022–3031.
  32. Morikawa Y, Tohya K, Ishida H, Matsuura N, Kakudo K. Different migration patterns of antigen-presenting cells correlate with Th1/Th2-type responses in mice. *Immunology.* 1995;85: 575–581.
  33. Nakashima Y, Deie M, Yanada S, Sharman P, Ochi M. Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells. *Int J Oncol.* 2005;27:965–971.
  34. Neff JR, Enneking WF. Adoptive immunotherapy in primary osteosarcoma: an interim report. *J Bone Joint Surg Am.* 1975; 57:145–148.
  35. Nishida H, Tsuchiya H, Tomita K. Re-implantation of destructive tumour tissue treated by liquid nitrogen cryotreatment induces anti-tumour activity against murine osteosarcoma. *J Bone Joint Surg Br.* 2008;90:1249–1255.
  36. Pelham JM, Gray JD, Flannery GR, Pimm MV, Baldwin RW. Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36. *Cancer Immunol Immunother.* 1983;15:210–216.
  37. Research Promotion Bureau, Life Sciences Divisions. Fundamental guidelines for proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology. Ministry of Education, Culture, Sports, Science and Technology, Notice No. 71. Available at: [http://www.lifescience.mext.go.jp/policies/pdf/an\\_material011.pdf](http://www.lifescience.mext.go.jp/policies/pdf/an_material011.pdf). Accessed October 29, 2007.
  38. Romieu R, Baratin M, Kayibanda M, Guillet JG, Viguier M. IFN-gamma-secreting Th cells regulate both the frequency and avidity of epitope-specific CD8 + T lymphocytes induced by peptide immunization: an ex vivo analysis. *Int Immunol.* 1998;10:1273–1279.
  39. Sabel MS, Kaufman CS, Whitworth P, Chang H, Stocks LH, Simmons R, Schultz M. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. *Ann Surg Oncol.* 2004;11:542–549.
  40. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. *J Immunol.* 1993;151:4209–4220.
  41. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Immunity to melanoma antigens: from self-tolerance to immunotherapy. *Adv Immunol.* 2006;90:243–295.
  42. Southam CM, Marcove R, Shanks E. Clinical trials of autogenous tumor vaccine for treatment of osteogenic sarcoma. *Proceedings of the Seventh National Cancer Conference.* Philadelphia, PA: JB Lippincott; 1973:91.



43. Tanzawa Y, Tsuchiya H, Yamamoto N, Sakayama K, Minato H, Tomita K. Histological examination of frozen autograft treated by liquid nitrogen removed 6 years after implantation. *J Orthop Sci.* 2008;13:259–264.
44. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. *Int Rev Immunol.* 2008;27:93–110.
45. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination: functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. *J Immunol.* 1996;156:3911–3918.
46. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, Yamamoto N. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. *Anticancer Res.* 1998;18:657–666.
47. Tsuchiya H, Tomita K, Mori Y, Asada N, Yamamoto N. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. *Clin Orthop Relat Res.* 1999;358:27–35.
48. Tsuchiya H, Wan SL, Sakayama K, Yamamoto N, Nishida H, Tomita K. Reconstruction using an autograft containing tumour treated by liquid nitrogen. *J Bone Joint Surg Br.* 2005;87:218–225.
49. Tsuchiya H, Yasutake H, Yokogawa A, Baba H, Ueda Y, Tomita K. Effect of chemotherapy combined with caffeine for osteosarcoma. *J Cancer Res Clin Oncol.* 1992;118:567–569.
50. Urano M, Tanaka C, Sugiyama Y, Miya K, Saji S. Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. *Cryobiology.* 2003;46:238–245.
51. Visonneau S, Cesano A, Jeglum KA, Santoli D. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104. *Clin Cancer Res.* 1999;5:1868–1875.
52. Warren RQ, Tsang KY. Induction of immunity to a human osteosarcoma-associated antigen in mice using anti-idiotypic antibodies. *Clin Immunol Immunopathol.* 1990;56:334–343.
53. Yamamoto N, Tsuchiya H, Tomita K. Effects of liquid nitrogen treatment on the proliferation of osteosarcoma and the biomechanical properties of normal bone. *J Orthop Sci.* 2003;8:374–380.



## Antitumor Effect after Radiofrequency Ablation of Murine Hepatoma Is Augmented by an Active Variant of CC Chemokine Ligand 3/Macrophage Inflammatory Protein-1 $\alpha$

Noriho Iida<sup>1</sup>, Yasunari Nakamoto<sup>1</sup>, Tomohisa Baba<sup>2</sup>, Hidetoshi Nakagawa<sup>1</sup>, Eishiro Mizukoshi<sup>1</sup>, Makoto Naito<sup>3</sup>, Naofumi Mukaida<sup>2</sup>, and Shuichi Kaneko<sup>1</sup>

### Abstract

Several chemokines are used for immunotherapy against cancers because they can attract immune cells such as dendritic and cytotoxic T cells to augment immune responses. Radiofrequency ablation (RFA) is used to locally eliminate cancers such as hepatocellular carcinoma (HCC), renal cell carcinoma, and lung cancer. Because HCC often recurs even after an eradicated treatment with RFA, additional immunotherapy is necessary. We treated tumor-bearing mice by administering ECI301, an active variant of CC chemokine ligand 3, after RFA. Mice were injected s.c. with BNL 1ME A.7R.1, a murine hepatoma cell line, in the bilateral flank. After the tumor became palpable, RFA was done on the tumor of one flank with or without ECI301. RFA alone eliminated the treated ipsilateral tumors and retarded the growth of contralateral non-RFA-treated tumors accompanied by massive T-cell infiltration. Injection of ECI301 augmented RFA-induced antitumor effect against non-RFA-treated tumors when administered to wild-type or *CCR5*-deficient but not *CCR1*-deficient mice. ECI301 also increased *CCR1*-expressing CD11c<sup>+</sup> cells in peripheral blood and RFA-treated tumors after RFA. Deficiency of *CCR1* impairs accumulation of CD11c<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> cells in RFA-treated tumors. Furthermore, in IFN- $\gamma$ -enzyme-linked immunospot assay, ECI301 augmented tumor-specific responses after RFA whereas deficiency of *CCR1* abolished this augmentation. Thus, we proved that ECI301 further augments RFA-induced antitumor immune responses in a *CCR1*-dependent manner. *Cancer Res*; 70(16); 6556–65. ©2010 AACR.

### Introduction

Chemokines are a class of candidate molecules for immunotherapy. Chemokines are presumed to play an essential role in the regulation of leukocyte trafficking and dendritic cell-T-cell interactions (1–4). In animal experiments, intratumoral use of chemokines, such as monocyte chemoattractant protein-1/CC chemokine ligand 2 (CCL2), macrophage inflammatory protein (MIP)-1 $\alpha$ /CCL3, or MIP-3 $\alpha$ /CCL20, succeeds in decreasing tumorigenesis accompanied by increase in the numbers of tumor-infiltrating dendritic, natural killer, or T cells (5–7). Thus, application of chemokines in immunotherapy is promising but needs further refinement before they can be used in clinical situations.

Radiofrequency ablation (RFA) is an eradicated treatment against cancers, such as hepatocellular carcinoma (HCC), re-

nal cell carcinoma, and lung cancer. RFA of HCC can generate HCC-specific T cells in peripheral blood (8). Activation of dendritic cells in human peripheral blood is also observed after this treatment (9). Thus, RFA can induce immunogenic tumor cell death and subsequently tumor-specific immune responses (8–11). However, multicentric development of HCC in the cirrhotic liver frequently results in tumor recurrence even after the apparent curative treatment of HCC by RFA (12). These observations suggest that RFA-induced tumor-specific immune responses are often not sufficient to prevent tumor recurrence. Thus, additional treatment modalities are required to augment HCC-specific immune responses.

CCL3/MIP-1 $\alpha$  can augment immune responses but problems arise because of its tendency to form large aggregates at high concentrations when administered systemically. Unlike human naïve CCL3, BB-10010 is generated by a single amino acid substitution of Asp26 to Ala and exhibits similar biological potencies, but rarely forms large aggregates (13). Based on its activity to mobilize bone marrow cells to peripheral blood, randomized clinical trials were performed to examine whether the combined administration of BB-10010 and chemotherapeutic agents can protect against chemotherapy-induced neutropenia. However, the myeloprotective effects of BB-10010 were not sufficient to warrant its use with chemotherapy (14). Concomitantly, several lines of evidence reveal that the administration of human recombinant CCL3

**Authors' Affiliations:** <sup>1</sup>Disease Control and Homeostasis, Graduate School of Medical Science, and <sup>2</sup>Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; and <sup>3</sup>Division of Cellular and Molecular Pathology, Niigata University Graduate School of Medicine, Niigata, Japan

**Corresponding Author:** Shuichi Kaneko, Disease Control and Homeostasis, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan. Phone: 81-76-265-2235; Fax: 81-76-234-4250; E-mail: skaneko@m-kanazawa.jp.

doi: 10.1158/0008-5472.CAN-10-0096

©2010 American Association for Cancer Research.

can mobilize activated T-cell and dendritic cell precursors into circulation (15, 16).

ECI301, which has the same amino acid sequence as BB-10010, was generated using the fission yeast (*Schizosaccharomyces pombe*) expression system. ECI301 can augment irradiation-induced tumor regression when administered systemically to mice bearing multiple subcutaneous tumors (17). Of interest is the fact that the effects were observed in both unirradiated and irradiated tumors. Thus, systemic ECI301 treatment can augment irradiation-induced tumor-specific systemic immunity. These observations prompted us to investigate the effects of ECI301 on RFA-treated mice. Here, we show that ECI301 further augments RFA-induced antitumor immune responses in a CCR1-dependent manner.

## Materials and Methods

### Mice

Seven- to 9-week-old specific pathogen-free female BALB/c mice were purchased from Charles River Japan and designated as wild-type (WT) mice. BALB/c-*nu/nu* mice were purchased from CLEA Japan. CCR1-deficient (CCR1<sup>-/-</sup>) mice were a gift from Dr. Philip M. Murphy (National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD); CCR5-deficient (CCR5<sup>-/-</sup>) mice were a gift from Dr. Kouji Matsushima (Department of Molecular Preventive Medicine, Tokyo University, Tokyo, Japan). All mice were backcrossed to BALB/c mice for 8 to 10 generations. All animal experiments were performed under specific pathogen-free conditions in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University (Japan).

### Tumor cell line

A murine HCC cell line, BNL 1ME A.7R.1 (BNL), was purchased from the American Type Culture Collection in 1998 and kept at low passage throughout the study. The cells were screened for bacteria, fungus, and *Mycoplasma* contamination by direct culture method in 2006 before start of the study. The cells were cultured in DMEM (Sigma Chemical Co.) containing 10% fetal bovine serum (FBS), 0.1 mmol/L nonessential amino acids, 1  $\mu$ mol/L sodium pyruvate, 2 mmol/L L-glutamine, 50  $\mu$ g/mL streptomycin, and 100 units/mL penicillin (Life Technologies, Inc.).

### Animal models

ECI301 was generated as previously described and provided by Effector Cell Institute, Inc. (17, 18). The left and right flanks of 7- to 9-week-old female WT, CCR1<sup>-/-</sup>, CCR5<sup>-/-</sup>, and *nu/nu* mice were injected s.c. with  $5 \times 10^5$  BNL cells in 100  $\mu$ L of PBS. Fourteen days later, when tumor size reached a diameter of 6 to 8 mm, tumors of one flank were treated using a radiofrequency generator (RITA 500PA, RITA Medical Systems) and needle as described below. On days 0, 2, and 4 after RFA, 20  $\mu$ g of ECI301 in 100  $\mu$ L of PBS were injected i.v. via the tail vein, whereas mice treated with RFA alone were injected with 100  $\mu$ L of PBS. Untreated tumor-bearing mice were used as controls. In another schedule, 2  $\mu$ g of ECI301 in 100  $\mu$ L of PBS were injected i.v. from day 0 to day 4 (5 con-

secutive days). The sizes of non-RFA-treated tumors on the contralateral flank were evaluated twice a week using calipers, and tumor volumes were calculated using the following formula: tumor volume (mm<sup>3</sup>) = (longest diameter)  $\times$  (shortest diameter)<sup>2</sup> / 2.

RFA-treated or non-RFA-treated tumors were excised at the indicated time intervals for immunohistochemical analysis and quantitative real-time reverse transcription-PCR (RT-PCR). Spleens and peripheral blood were removed from the mice at the indicated time intervals for flow cytometric analysis and enzyme-linked immunosorbent assay (ELISPOT).

### Radiofrequency ablation

Mice were anesthetized by i.p. injection of Somnopentyl (Schering-Plough Animal Health) and carefully shaved in the tumor area. After placing the mice onto an aluminum plate attached with an electricity-conducting pad, an RFA needle of expandable electrode with maximum dimension of 20 mm (70SB 2 cm; RITA Medical Systems) was inserted into the middle of the tumors and expanded at 2 or 3 mm. RFA treatments were done using a radiofrequency generator at a power output of 25 W for 1.5 minutes and the temperature of the needle tips reached 70°C to 80°C.

### Immunohistochemical analysis

The removed tumor tissues were embedded in Sakura Tissue-Tek optimum cutting temperature (OCT) compound (Sakura Finetek) as frozen tissues. Cryostat sections of the frozen tissues were fixed with 4% paraformaldehyde in PBS and stained with rat anti-mouse CD4 (BD Biosciences), rat anti-mouse CD8a (BD Biosciences), hamster anti-mouse CD11c (BD Biosciences), and rat anti-mouse F4/80 antibodies (Serotec) overnight at 4°C. The sections were then incubated with biotinylated rabbit anti-rat IgG (DakoCytomation) or biotinylated mouse anti-hamster IgG (BD Biosciences) for 1 hour at room temperature. The immune complexes were visualized using the Catalyzed Signal Amplification System (DakoCytomation) or the Vectastain Elite ABC and DAB substrate kits (Vector Laboratories) according to the manufacturer's instructions. As a negative control, rat IgG (Cosmo Bio) or hamster IgG (BD Biosciences) was used instead of specific primary antibodies. The numbers of positive cells in each animal were counted in 10 randomly selected fields at 400-fold magnification by an examiner without any prior knowledge of the experimental procedures.

### Double-color immunofluorescence analysis

Tumor tissues were embedded in OCT compound as frozen tissues. After fixation with 4% paraformaldehyde/PBS, cryostat sections were stained with the combinations of anti-CD4 and goat anti-mouse CCR1 (Santa Cruz Biotechnology), anti-CD8a and anti-CCR1, anti-F4/80 and anti-CCR1, phycoerythrin (PE)-conjugated hamster anti-CD11c (BD Biosciences) and anti-CCR1, anti-F4/80 and goat anti-mouse CCL3 (R&D Systems), and anti-F4/80 and goat anti-mouse CCL4 antibodies (R&D). After extensive washing, AF488 donkey anti-rat IgG (Invitrogen) was used as a secondary antibody to detect CD4<sup>+</sup>, CD8a<sup>+</sup>, or F4/80<sup>+</sup> cells. Simultaneously,

AF546- or AF488-donkey anti-goat IgG (Invitrogen) was used to detect CCR1<sup>+</sup>, CCL3<sup>+</sup>, or CCL4<sup>+</sup> cells. The sections were observed using a confocal microscope (LSM 510 META, Zeiss).


#### Quantitative real-time RT-PCR

Total RNA was extracted from the resected tumor using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. After treating the RNA preparations with RNase-free DNase I (Qiagen) to remove residual DNA, cDNA was synthesized as described previously (19). Quantitative real-time PCR was done on a StepOne Real-Time PCR System (Applied Biosystems) using the comparative  $C_T$  quantification method. TaqMan Gene Expression Assays (Applied Biosystems) containing specific primers and probes [accession numbers: CCL3, Mm00441258\_m1; CCL4, Mm00443111\_m1; CCL5, Mm01302428\_m1; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Mm99999915\_g1] and TaqMan Fast Universal PCR Master Mix were used with 10 ng of cDNA to quantify the expression levels of CCL3, CCL4, and CCL5. Reactions were performed for 20 seconds at 95°C followed by 40 cycles of 1 second at 95°C and 20 seconds at 60°C. GAPDH was amplified as an internal control and its  $C_T$  values were subtracted from the  $C_T$  values of the target genes

( $\Delta C_T$ ). The  $\Delta C_T$  values of tumors after RFA with or without ECI301 were compared with the  $\Delta C_T$  values of tumors of untreated mice.

#### Enzyme-linked immunospot assay

To prepare tumor lysates, BNL or CT26 cells were suspended in PBS and subjected to four cycles of rapid freezing in liquid nitrogen and thawing at 55°C. The lysate was spun at 15,000 rpm to remove particulate cellular debris. After harvesting murine spleens on day 21 after RFA, mononuclear cells were isolated by centrifugation through a Histopaque-1083 density gradient (Sigma Chemical). ELISPOT was performed using an IFN- $\gamma$ -ELISPOT kit (Mabtech). Ninety-six-well plates coated with anti-mouse IFN- $\gamma$  antibody were blocked for 2 hours with RPMI 1640 (Sigma Chemical) containing 10% FBS. Two hundred fifty thousand splenic mononuclear cells were added in triplicate cultures of RPMI 1640 containing 10% FBS together with BNL or CT26 lysates at a tumor cell-to-mononuclear cell ratio of 2:1. After 48 hours of culture, the plates were washed eight times with sterile PBS and further incubated for 2 hours with biotinylated anti-mouse IFN- $\gamma$  antibody. After another eight washes, alkaline phosphatase-conjugated streptavidin was added to these



**Figure 1.** ECI301-induced augmentation of antitumor effects after RFA. WT mice were injected s.c. with  $5 \times 10^5$  BNL cells into the left and right flanks. Fourteen days later, when tumors became palpable, tumors of one flank were treated using the RFA generator and needle. On day 0, 2, and 4 after RFA, 20  $\mu$ g of ECI301 in 100  $\mu$ L of PBS were injected i.v. into each mouse, whereas mice treated with RFA alone were injected with 100  $\mu$ L of PBS. Tumor-bearing untreated mice were observed as controls. A, macroscopic appearances of the mice on day 14 after RFA are shown. Arrowheads indicate the scar after RFA. Representative results are from at least 10 mice in each group. B, non-RFA-treated tumor volumes after RFA with or without ECI301 were measured twice a week. Points, mean; bars, SE. \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ . C, volumes of non-RFA-treated tumors on day 14 after RFA. In addition to the groups described in B, tumor volumes were determined in animals receiving 2  $\mu$ g of ECI301 in 100  $\mu$ L of PBS i.v. from day 0 to day 4 (5 consecutive days) after RFA and those receiving 20  $\mu$ g of ECI301 alone without RFA. Columns, mean; bars, SE. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ , compared with untreated mice.